{"id":2313,"date":"2018-06-04T11:00:44","date_gmt":"2018-06-04T11:00:44","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=2313"},"modified":"2018-06-04T11:00:44","modified_gmt":"2018-06-04T11:00:44","slug":"enyo-pharma-realise-une-levee-de-fonds-de-40-millions-deuros-lors-dune-serie-b","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-realise-une-levee-de-fonds-de-40-millions-deuros-lors-dune-serie-b\/","title":{"rendered":"ENYO Pharma r\u00e9alise une lev\u00e9e de fonds de 40 millions d\u2019euros lors d\u2019une S\u00e9rie B"},"content":{"rendered":"<p>Lyon, le 4 Juin 2018 \u2013 ENYO Pharma, une entreprise biopharmaceutique au stade clinique qui d\u00e9veloppe des candidats m\u00e9dicaments innovants en imitant la strat\u00e9gie des virus \u00e0 moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui le succ\u00e8s de sa lev\u00e9e de fonds de 40 millions d\u2019euros provenant d\u2019investisseurs am\u00e9ricains et europ\u00e9ens. Cette lev\u00e9e permettra \u00e0 l\u2019entreprise de financer les deux essais cliniques de phase II de son compos\u00e9 EYP001, \u00e0 la fois pour l\u2019h\u00e9patite B chronique (HBV) et la NASH. Un deuxi\u00e8me compos\u00e9 devrait \u00e9galement entrer en clinique en 2019. <\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2018\/06\/ENYO-Pharma-Press-Release-Series-B-French.pdf\" target=\"_blank\" rel=\"noopener\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiquer complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, le 4 Juin 2018 \u2013 ENYO Pharma, une entreprise biopharmaceutique au stade clinique qui d\u00e9veloppe des candidats m\u00e9dicaments innovants en imitant la strat\u00e9gie des virus \u00e0 moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui le succ\u00e8s de sa lev\u00e9e de fonds de 40 millions d\u2019euros provenant d\u2019investisseurs am\u00e9ricains et europ\u00e9ens. Cette lev\u00e9e permettra \u00e0 l\u2019entreprise de financer les deux essais cliniques de phase II de son compos\u00e9 EYP001, \u00e0 la fois pour l\u2019h\u00e9patite B chronique (HBV) et la NASH.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-realise-une-levee-de-fonds-de-40-millions-deuros-lors-dune-serie-b\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-2313","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, le 4 Juin 2018 \u2013 ENYO Pharma, une entreprise biopharmaceutique au stade clinique qui d\u00e9veloppe des candidats m\u00e9dicaments innovants en imitant la strat\u00e9gie des virus \u00e0 moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui le succ\u00e8s de sa lev\u00e9e de fonds de 40 millions d\u2019euros provenant d\u2019investisseurs am\u00e9ricains et europ\u00e9ens. Cette lev\u00e9e permettra \u00e0&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2313"}],"version-history":[{"count":1,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2313\/revisions"}],"predecessor-version":[{"id":2314,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2313\/revisions\/2314"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=2313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=2313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}